US7013219B2
(en)
*
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US7030215B2
(en)
*
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US20020164575A1
(en)
*
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
WO2001040798A2
(en)
*
|
1999-12-06 |
2001-06-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
US20020055112A1
(en)
*
|
2000-08-26 |
2002-05-09 |
Nila Patil |
Methods for reducing complexity of nucleic acid samples
|
US20020164634A1
(en)
*
|
2000-08-26 |
2002-11-07 |
Perlegen Sciences, Inc. |
Methods for reducing complexity of nucleic acid samples
|
WO2002063037A2
(en)
*
|
2001-02-02 |
2002-08-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Method for identifying functional nucleic acids
|
ATE513040T1
(de)
*
|
2001-08-17 |
2011-07-15 |
Toolgen Inc |
Zinkfingerdomänenbibliotheken
|
WO2003048345A1
(en)
|
2001-12-07 |
2003-06-12 |
Toolgen, Inc. |
Phenotypic screen of chimeric proteins
|
US20040259258A1
(en)
*
|
2001-12-07 |
2004-12-23 |
Kim Jin-Soo |
Regulation of prokaryotic gene expression with zinc finger proteins
|
ATE347593T1
(de)
|
2002-01-23 |
2006-12-15 |
Univ Utah Res Found |
Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
|
WO2003066828A2
(en)
*
|
2002-02-07 |
2003-08-14 |
The Scripps Research Institute |
Zinc finger libraries
|
US20030180777A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Victor Bartsevich |
Rapid identification of transcriptional regulatory domains
|
WO2004037977A2
(en)
|
2002-09-05 |
2004-05-06 |
California Institute Of Thechnology |
Use of chimeric nucleases to stimulate gene targeting
|
WO2004022575A2
(en)
*
|
2002-09-05 |
2004-03-18 |
Toolgen, Inc. |
Bioinformatics analysis of cellular effects of artificial transcription factors
|
US20050069896A1
(en)
*
|
2002-09-12 |
2005-03-31 |
Horvitz H. Robert |
Rb pathway and chromatin remodeling genes that antagonize let-60 Ras signaling
|
US20070178454A1
(en)
*
|
2002-10-21 |
2007-08-02 |
Joung J K |
Context sensitive paralell optimization of zinc finger dna binding domains
|
AU2003304087A1
(en)
*
|
2002-10-23 |
2004-11-26 |
The General Hospital Corporation |
Methods for producing zinc finger proteins that bind to extended dna target sequences
|
WO2004046387A1
(en)
*
|
2002-11-15 |
2004-06-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for analysis of regulatory sequences
|
JP2006508675A
(ja)
*
|
2002-12-09 |
2006-03-16 |
トゥールゲン・インコーポレイテッド |
調節性ジンクフィンガータンパク質
|
US20090124514A1
(en)
*
|
2003-02-26 |
2009-05-14 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
US20060183132A1
(en)
*
|
2005-02-14 |
2006-08-17 |
Perlegen Sciences, Inc. |
Selection probe amplification
|
US20050100911A1
(en)
*
|
2003-08-06 |
2005-05-12 |
Perlegen Sciences, Inc. |
Methods for enriching populations of nucleic acid samples
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
EP1789095A2
(en)
|
2004-09-16 |
2007-05-30 |
Sangamo Biosciences Inc. |
Compositions and methods for protein production
|
JP5237799B2
(ja)
|
2005-06-27 |
2013-07-17 |
エグゼリクシス パテント カンパニー エルエルシー |
ピラゾールベースのlxrモジュレーター
|
US7718131B2
(en)
*
|
2005-07-06 |
2010-05-18 |
Genetix Limited |
Methods and apparatus for imaging and processing of samples in biological sample containers
|
US20070148674A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Wisconsin Alumni Research Foundation (Warf) |
Optical fingerprinting of nucleic acid sequences
|
WO2007106603A2
(en)
*
|
2006-01-06 |
2007-09-20 |
The Scripps Research Institute |
Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
|
KR100756055B1
(ko)
*
|
2006-01-27 |
2007-09-07 |
연세대학교 산학협력단 |
신생혈관 생성을 조절하는 재조합 아데노바이러스
|
WO2007106488A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Wyeth |
Modulators of gluconeogenesis
|
WO2007136685A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
JP5551432B2
(ja)
|
2006-05-25 |
2014-07-16 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
遺伝子不活性化のための方法と組成物
|
CA2651494C
(en)
*
|
2006-05-25 |
2015-09-29 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
AU2007284748B2
(en)
|
2006-08-11 |
2013-05-16 |
Corteva Agriscience Llc |
Zinc finger nuclease-mediated homologous recombination
|
JP5188504B2
(ja)
|
2006-11-13 |
2013-04-24 |
サンガモ バイオサイエンシズ インコーポレイテッド |
ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物
|
WO2009009086A2
(en)
|
2007-07-12 |
2009-01-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
AR068559A1
(es)
*
|
2007-09-27 |
2009-11-18 |
Sangamo Biosciences Inc |
Proteinas de dedo de zinc obtenidas por ingenieria dirigidas a genes de 5-enolpiruvilshikimato-3-fosfatosintetasa
|
EP2205729A2
(en)
*
|
2007-09-27 |
2010-07-14 |
Sangamo BioSciences, Inc. |
Genomic editing in zebrafish using zinc finger nucleases
|
EP2597155B1
(en)
|
2007-10-25 |
2016-11-23 |
Sangamo BioSciences, Inc. |
Methods and compositions for targeted integration
|
WO2009146179A1
(en)
*
|
2008-04-15 |
2009-12-03 |
University Of Iowa Research Foundation |
Zinc finger nuclease for the cftr gene and methods of use thereof
|
CA2726768C
(en)
|
2008-06-10 |
2016-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
KR20160015400A
(ko)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
KR101673566B1
(ko)
|
2008-10-29 |
2016-11-07 |
상가모 바이오사이언스 인코포레이티드 |
글루타민 신테타제 유전자 발현을 불활성화시키기 위한 방법 및 조성물
|
WO2010065123A1
(en)
|
2008-12-04 |
2010-06-10 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
CA2749965C
(en)
*
|
2009-02-04 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
AU2010226313B2
(en)
|
2009-03-20 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Modification of CXCR4 using engineered zinc finger proteins
|
EP2419511B1
(en)
*
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
US9234016B2
(en)
*
|
2009-07-28 |
2016-01-12 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for treating trinucleotide repeat disorders
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
EA031322B1
(ru)
|
2010-01-22 |
2018-12-28 |
Дау Агросайенсиз Ллс |
Клетка или клеточная линия для экспрессии экзогенных нуклеотидных последовательностей и применение клетки или клеточной линии
|
PT2534173T
(pt)
|
2010-02-08 |
2019-10-31 |
Sangamo Therapeutics Inc |
Semidomínios de clivagem manipulados
|
JP2013518602A
(ja)
*
|
2010-02-09 |
2013-05-23 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
部分的に一本鎖のドナー分子による標的化ゲノム改変
|
CA2796600C
(en)
|
2010-04-26 |
2019-08-13 |
Sangamo Biosciences, Inc. |
Genome editing of a rosa locus using zinc-finger nucleases
|
EP3156062A1
(en)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
EP2596011B1
(en)
|
2010-07-21 |
2018-10-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a hla locus
|
WO2012047598A1
(en)
|
2010-09-27 |
2012-04-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
RU2608643C2
(ru)
|
2010-10-12 |
2017-01-23 |
Дзе Чилдрен`З Хоспитал Оф Филадельфия |
Способы и композиции для лечения гемофилии в
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
JP6214530B2
(ja)
|
2011-07-15 |
2017-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
転写活性化因子様エフェクターの組立て方法
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
CA2841541C
(en)
|
2011-07-25 |
2019-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US9394545B2
(en)
|
2011-09-21 |
2016-07-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
JP6188703B2
(ja)
|
2011-10-27 |
2017-08-30 |
サンガモ セラピューティクス, インコーポレイテッド |
Hprt遺伝子座を修飾するための方法および組成物
|
JP6144691B2
(ja)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス, インコーポレイテッド |
修飾されたdna結合タンパク質およびその使用
|
CN108285491B
(zh)
|
2012-02-29 |
2021-08-10 |
桑格摩生物科学股份有限公司 |
治疗亨廷顿氏病的方法和组合物
|
DK2847335T3
(en)
|
2012-04-25 |
2018-08-13 |
Regeneron Pharma |
NUCLEASED MEDIUM TARGETING WITH LARGE TARGET VECTORS
|
MX369788B
(es)
*
|
2012-05-02 |
2019-11-21 |
Dow Agrosciences Llc |
Modificacion dirigida de deshidrogenasa de malato.
|
BR112014027813A2
(pt)
|
2012-05-07 |
2017-08-08 |
Dow Agrosciences Llc |
métodos e composições para integração de transgenes direcionada mediada por nuclease
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
DK3196301T3
(en)
|
2012-07-11 |
2019-01-14 |
Sangamo Therapeutics Inc |
METHODS AND COMPOSITIONS FOR TREATING MONOGENIC DISEASES
|
EP2872154B1
(en)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Methods and compositions for delivery of biologics
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
LT2890780T
(lt)
|
2012-08-29 |
2020-11-10 |
Sangamo Therapeutics, Inc. |
Būdai ir kompozicijos, skirti genetinės būklės gydymui
|
EP3750999B1
(en)
|
2012-09-04 |
2022-06-29 |
The Scripps Research Institute |
Chimeric polypeptides having targeted binding specificity
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
UA119135C2
(uk)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб отримання трансгенної рослини
|
RU2665811C2
(ru)
|
2012-09-07 |
2018-09-04 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Локусы fad3 для выполнения операций и соответствующие связывающиеся со специфическими сайтами-мишенями белки, способные к вызову направленных разрывов
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
WO2014089212A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
EP2928303A4
(en)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
|
CA2900338A1
(en)
|
2013-02-07 |
2014-08-14 |
The General Hospital Corporation |
Tale transcriptional activators
|
EP2958996B1
(en)
|
2013-02-25 |
2019-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
US11332719B2
(en)
*
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
JP6980380B2
(ja)
|
2013-03-15 |
2021-12-15 |
ザ ジェネラル ホスピタル コーポレイション |
短縮ガイドRNA(tru−gRNA)を用いたRNA誘導型ゲノム編集の特異性の増大
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
JP6346266B2
(ja)
|
2013-03-21 |
2018-06-20 |
サンガモ セラピューティクス, インコーポレイテッド |
操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
|
PL3456831T3
(pl)
|
2013-04-16 |
2021-12-06 |
Regeneron Pharmaceuticals, Inc. |
Ukierunkowana modyfikacja genomu szczura
|
JP2016518142A
(ja)
|
2013-05-10 |
2016-06-23 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
EP3988654A1
(en)
|
2013-08-28 |
2022-04-27 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
WO2015057980A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
EP3057432B1
(en)
|
2013-10-17 |
2018-11-21 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
UY35812A
(es)
|
2013-11-04 |
2015-05-29 |
Dow Agrosciences Llc |
?loci de maíz óptimos?.
|
CA2928855A1
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal maize loci
|
CN106232821A
(zh)
|
2013-11-04 |
2016-12-14 |
美国陶氏益农公司 |
最优大豆座位
|
PT3066201T
(pt)
|
2013-11-07 |
2018-06-04 |
Massachusetts Inst Technology |
Métodos e composições relacionadas com crispr com arng reguladores
|
KR102431079B1
(ko)
|
2013-11-11 |
2022-08-11 |
상가모 테라퓨틱스, 인코포레이티드 |
헌팅턴병을 치료하기 위한 방법 및 조성물
|
WO2015073683A2
(en)
|
2013-11-13 |
2015-05-21 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
AU2014363991B2
(en)
|
2013-12-09 |
2020-08-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for genome engineering
|
RU2685914C1
(ru)
|
2013-12-11 |
2019-04-23 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
US10072066B2
(en)
|
2014-02-03 |
2018-09-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
AU2015218576B2
(en)
|
2014-02-24 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
JP2017515819A
(ja)
|
2014-05-08 |
2017-06-15 |
サンガモ セラピューティクス, インコーポレイテッド |
ハンチントン病を処置するための方法および組成物
|
EP3142707A4
(en)
|
2014-05-13 |
2018-02-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for prevention or treatment of a disease
|
WO2015188056A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
KR102374379B1
(ko)
|
2014-06-06 |
2022-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 좌를 변형시키는 방법 및 조성물
|
IL286474B2
(en)
|
2014-06-23 |
2023-11-01 |
Massachusetts Gen Hospital |
Genome-wide random identification of DSBS assessed by sequencing (guide-sequence)
|
PT3161128T
(pt)
|
2014-06-26 |
2018-11-21 |
Regeneron Pharma |
Métodos e composições para modificações genéticas alvejadas e métodos de utilização
|
US20170142942A1
(en)
|
2014-07-14 |
2017-05-25 |
Washington State University |
Nanos knock-out that ablates germline cells
|
EP3169773B1
(en)
|
2014-07-15 |
2023-07-12 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
PL3194570T3
(pl)
|
2014-09-16 |
2021-12-20 |
Sangamo Therapeutics, Inc. |
Sposoby i kompozycje do inżynierii genomowej w której pośredniczy nukleaza i korekty hematopoetycznych komórek macierzystych
|
IL287561B2
(en)
|
2014-10-01 |
2024-03-01 |
Massachusetts Gen Hospital |
Methods for increasing the efficiency of nuclease-induced homology-directed repair
|
PL3221457T3
(pl)
|
2014-11-21 |
2019-09-30 |
Regeneron Pharmaceuticals, Inc. |
Sposoby i kompozycje do celowanej modyfikacji genetycznej z zastosowaniem sparowanych przewodników RNA
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
WO2016100819A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
WO2016161446A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
MX2017014446A
(es)
|
2015-05-12 |
2018-06-13 |
Sangamo Therapeutics Inc |
Regulacion de expresion genica mediada por nucleasa.
|
WO2016193945A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
JP6954890B2
(ja)
|
2015-07-13 |
2021-10-27 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US10091975B2
(en)
|
2015-08-06 |
2018-10-09 |
The Curators Of The University Of Missouri |
Pathogen-resistant animals having modified CD163 genes
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
AU2016319110B2
(en)
|
2015-09-11 |
2022-01-27 |
The General Hospital Corporation |
Full interrogation of nuclease DSBs and sequencing (FIND-seq)
|
MX2018003491A
(es)
|
2015-09-23 |
2018-09-06 |
Sangamo Therapeutics Inc |
Represores de htt y usos de estos.
|
AU2016331185A1
(en)
|
2015-09-30 |
2018-04-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq)
|
JP7067793B2
(ja)
|
2015-10-23 |
2022-05-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸塩基編集因子およびその使用
|
KR20180069054A
(ko)
|
2015-10-28 |
2018-06-22 |
상가모 테라퓨틱스, 인코포레이티드 |
간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
EA201891212A1
(ru)
|
2015-12-18 |
2019-01-31 |
Сангамо Терапьютикс, Инк. |
Адресная дезорганизация клеточного рецептора гкгс
|
EP3389677A4
(en)
|
2015-12-18 |
2019-05-22 |
Sangamo Therapeutics, Inc. |
TARGETED DESTRUCTION OF THE T-CELL RECEPTOR
|
SG11201805680SA
(en)
|
2016-01-15 |
2018-07-30 |
Sangamo Therapeutics Inc |
Methods and compositions for the treatment of neurologic disease
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
MX2018014599A
(es)
|
2016-05-27 |
2019-02-28 |
Aadigen Llc |
Peptidos y nanoparticulas para suministro intracelular de moleculas editoras de genoma.
|
CA3030783A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
BR112019003100A2
(pt)
|
2016-08-24 |
2019-07-09 |
Sangamo Therapeutics Inc |
regulação da expressão gênica usando nucleases manipuladas
|
WO2018039448A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
EP3509645A4
(en)
|
2016-09-07 |
2020-06-17 |
Sangamo Therapeutics, Inc. |
MODULATION OF LIVER GENES
|
CA3038690A1
(en)
|
2016-10-05 |
2018-04-12 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
EP3525803B1
(en)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
WO2018071892A1
(en)
|
2016-10-14 |
2018-04-19 |
Joung J Keith |
Epigenetically regulated site-specific nucleases
|
MX2019004487A
(es)
|
2016-10-20 |
2020-02-07 |
Sangamo Therapeutics Inc |
Metodos y composiciones para el tratamiento de la enfermedad de fabry.
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
KR20190085529A
(ko)
|
2016-12-01 |
2019-07-18 |
상가모 테라퓨틱스, 인코포레이티드 |
Tau 조절제 및 그것의 전달을 위한 방법 및 조성물
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
WO2018106782A1
(en)
|
2016-12-08 |
2018-06-14 |
Case Western Reserve University |
Methods and compositions for enhancing functional myelin production
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
EP3592777A1
(en)
|
2017-03-10 |
2020-01-15 |
President and Fellows of Harvard College |
Cytosine to guanine base editor
|
KR20190130613A
(ko)
|
2017-03-23 |
2019-11-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
AU2018250161B2
(en)
|
2017-04-03 |
2024-04-04 |
Encoded Therapeutics, Inc. |
Tissue selective transgene expression
|
EP3615510B1
(en)
|
2017-04-28 |
2024-03-27 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
JP2020518245A
(ja)
|
2017-05-03 |
2020-06-25 |
サンガモ セラピューティクス, インコーポレイテッド |
嚢胞性線維症膜貫通コンダクタンス制御因子(cftr)遺伝子の改変のための方法および組成物
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
AU2018272067A1
(en)
|
2017-05-25 |
2019-11-28 |
The General Hospital Corporation |
Base editors with improved precision and specificity
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
MX2020000676A
(es)
|
2017-07-18 |
2021-05-14 |
Csl Behring Gene Therapy Inc |
Composiciones y metodos para tratar beta-hemoglobinopatias.
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
USES OF BASIC EDITORS ADENOSINE
|
US11661611B2
(en)
|
2017-11-09 |
2023-05-30 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
|
BR112020014140A2
(pt)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
inibidores de dna-pk
|
CN111770921B
(zh)
|
2018-01-17 |
2024-03-22 |
沃泰克斯药物股份有限公司 |
用于提高基因组编辑效率的喹喔啉酮化合物,组合物,方法和试剂盒
|
KR20200110685A
(ko)
|
2018-01-17 |
2020-09-24 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제
|
CN111954540A
(zh)
|
2018-02-08 |
2020-11-17 |
桑格摩生物治疗股份有限公司 |
工程化靶标特异性核酸酶
|
JP2021520211A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現するt細胞、関連ポリヌクレオチド、および方法
|
JP2021520202A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
CA3100034A1
(en)
|
2018-05-11 |
2019-11-14 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
AU2019326408A1
(en)
|
2018-08-23 |
2021-03-11 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
US20210348177A1
(en)
|
2018-09-05 |
2021-11-11 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
EP4234570A3
(en)
|
2018-09-18 |
2023-12-13 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
US20220389395A1
(en)
|
2018-10-29 |
2022-12-08 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
KR20210094609A
(ko)
|
2018-11-28 |
2021-07-29 |
포티 세븐, 인코포레이티드 |
절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
|
BR112021013654A2
(pt)
|
2019-01-11 |
2021-09-14 |
Acuitas Therapeutics, Inc. |
Lipídeos para liberação de nanopartículas lipídicas de agentes ativos
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
CN112805026A
(zh)
|
2019-02-06 |
2021-05-14 |
桑格摩生物治疗股份有限公司 |
用于治疗i型黏多糖贮积症的方法
|
US11866469B2
(en)
|
2019-02-06 |
2024-01-09 |
Klogenix Llc |
DNA binding proteins and uses thereof
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
EP3942040A1
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
BR112021019448A2
(pt)
|
2019-04-02 |
2021-11-30 |
Sangamo Therapeutics Inc |
Métodos para o tratamento de beta-talassemia
|
CA3136119A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
EP3956349A1
(en)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
EP4007596A1
(en)
|
2019-08-01 |
2022-06-08 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
KR20220068222A
(ko)
|
2019-08-23 |
2022-05-25 |
사나 바이오테크놀로지, 인크. |
Cd24 발현 세포 및 이의 용도
|
DK3812472T3
(da)
|
2019-10-21 |
2023-02-20 |
Univ Freiburg Albert Ludwigs |
Virkelig uvildig in vitro-undersøgelse til profilering af off-target-aktivitet af en eller flere målspecifikke programmerbare nukleaser i celler (abnoba-seq)
|
EP4051323A1
(en)
|
2019-11-01 |
2022-09-07 |
Sangamo Therapeutics, Inc. |
Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
|
TW202132565A
(zh)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Gin重組酶變異體
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
EP4100519A2
(en)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
JP2023520997A
(ja)
|
2020-03-25 |
2023-05-23 |
サナ バイオテクノロジー,インコーポレイテッド |
神経学的障害及び神経学的病態の処置のための低免疫原性神経細胞
|
US11091524B1
(en)
|
2020-04-22 |
2021-08-17 |
Houston Gene Therapeutics Llc |
Compositions for treatment of vascular disease
|
US20230159913A1
(en)
|
2020-04-28 |
2023-05-25 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
US20230212613A1
(en)
|
2020-05-06 |
2023-07-06 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
JP2023525510A
(ja)
|
2020-05-06 |
2023-06-16 |
セレクティス ソシエテ アノニム |
治療用タンパク質の送達のために細胞を遺伝子改変する方法
|
CN111549061A
(zh)
*
|
2020-05-07 |
2020-08-18 |
西南大学 |
一种高通量筛选真核生物细胞响应环境极端pH的靶点基因的方法
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
CN115835873A
(zh)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
用于产生表达重组受体的供体分批细胞的方法
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
KR20230074718A
(ko)
|
2020-08-13 |
2023-05-31 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포로 감작된 환자를 치료하는 방법 및 관련 방법 및 조성물
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
US20240000051A1
(en)
|
2020-11-16 |
2024-01-04 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
IL303473A
(en)
|
2020-12-31 |
2023-08-01 |
Sana Biotechnology Inc |
Methods and compositions for modulating CAR-T activity
|
JP2024507533A
(ja)
|
2021-02-19 |
2024-02-20 |
ビーム・セラピューティクス・インコーポレイテッド |
遺伝子治療のための組み換え狂犬病ウイルス
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022251367A1
(en)
|
2021-05-27 |
2022-12-01 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
WO2023287827A2
(en)
|
2021-07-14 |
2023-01-19 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
KR20240053673A
(ko)
|
2021-08-11 |
2024-04-24 |
사나 바이오테크놀로지, 인크. |
저면역원성 세포 내 유전자 발현을 변경하기 위한 유도성 시스템
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
CA3230629A1
(en)
|
2021-09-08 |
2023-03-16 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|